The Nobuto Yamamoto Patents

Link to another GcMAF patent, not Dr. Yamamoto's

Here is a list and summary of the US patents held by Dr. Nobuto Yamamoto.

US Patent 5,177,002. Filed - August 31, 1990. In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor.

Abstract : A novel, potent macrophage activating factor is prepared in vitro by treating glycosylated human group-specific component, also known as human vitamin D-binding protein, with glycosidases. Group-specific component, which is isolated from retired blood by known procedures, is thus readily converted to a highly potent macrophage activating factor.
- - - - - - -

US Patent 5,177,001. Filed September 30, 1991 - In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor

Abstract: A novel macrophage activating factor is prepared in vitro by treating glycosylated mammalian vitamin D-binding protein with glycosidases. Vitamin D-binding protein, which is isolated from blood or plasma of animals by known procedures, is thus readily converted to a highly potent macrophage activating factor.

- - - - - - -
European Patent number EP19920919890, Filed September 2, 1992.

Macrophage Activating Factor From Animal Vitamin D-binding Protein.

- - - - - - -

US Patent 5,326,749 Filed January 4, 1993. - Macrophage activating factor from vitamin D binding protein.

Abstract :A novel macrophage activating factor is prepared in vitro by treating glycosated vitamin D-binding protein with glycosidases. Vitamin D-binding protein, which is isolated from blood or plasma of mammals by known procedures, is thus readily converted to a highly potent macrophage activating factor.

• Contains Phagocytosis Assay information

US Patent 5,620,846 Filed June 7, 1995. Diagnostic and prognostic indices for cancer and aids

Abstract: Cancerous cells and HIV-infected cells secrete .alpha.-N-acetylgalactosaminidase into the blood stream, resulting in deglycosylation of serum Gc protein. This inactivates the MAF precursor activity of Gc protein, leading to immunosuppression. Thus, both .alpha.-N-acetylgalactosaminidase activity and MAF precursor activity of Gc protein in patient blood stream can serve as diagnostic and prognostic indices. In one embodiment is disclosed a process for determining macrophage activating factor precursor activity in plasma or serum of a person suspected of having cancer or HIV, comprising the step of quantifying in the plasma or serum an amount of vitamin D.sub.3 -binding protein. The determination of the macrophage activating factor precursor activity provides an indication of the patient's capability to activate its own monocytes/macrophages. In another embodiment is disclosed a process for determining macrophage activating factor precursor activity in plasma or serum of a person suspected of having cancer or HIV comprising the step of quantifying in the plasma or serum an amount of .alpha.-N-acetylgalactosaminidase activity. Determining the .alpha.-N-acetylgalactosaminidase activity in the plasma or serum provides an indication of a quantity of malignant cells (or HIV) in the plasma or serum.

- - - - - - -

US Patent 6,410,269 - Filed March 19, 1996. Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis.

Abstract: Vitamin D-binding protein (Gc protein) and its small domain (approximately 1/5 of the Gc peptide also known as domain III) were cloned via a baculovirus vector. The cloned Gc protein and the cloned domain (Cd) peptide were treated with immobilized .beta.-galactosidase and sialidase to yield macrophage activating factors, GcMAFc and CdMAF, respectively. These cloned macrophage activating factors and GcMAF are to be used for therapy of cancer, HIV-infection and osteopetrosis, and may also be used as adjuvants for immunization and vaccination.

- - - - - - -
Determination of alpha-N-acetylgalactosaminidase activity.

U.S. Patent application number EP20030075633. Filed June 5, 1996.
Abstract: A process for determining alpha -N-acetylgalactosaminidase activity in plasma or serum of patients with cancer or human immunodeficiency virus (HIV) and an ELISA process for determining alpha -N-acetylgalactosaminidase activity as an antigen in the same.

Links:
http://v3.espacenet.com/publicationDetails/biblio?CC=EP&NR=1340815&KC=&FT=Ehttp://www.freepatentsonline.com/EP1340815.html

- - - - - - -

US Patent 5,712,104 Filed January 6, 1997. Diagnostic and prognostic elisa assays of serum or plasma .alpha.-N-acetylgalactosaminidase for cancer.

Abstract Cancerous cells and HIV- and influenza virus-infected cells secrete .alpha.-N-acetylgalactosaminidase into blood stream, resulting in deglycosylation of Gc protein. This inactivates the MAF precursor activity of Gc protein, leading to immunosuppression. Thus, .alpha.-N-acetylgalactosaminidase activity in patient bloodstream can serve as diagnostic and prognostic index. Antibody-sandwich ELISA method and kits for cancer, HIV and influenza specific .alpha.-N-acetylgalactosaminidase as an antigen were developed to detect serum or plasma .alpha.-N-acetylgalactosaminidase in cancer and AIDS/HIV-infected and influenza patients and used as a diagnostic/prognostic index.
- - - - - - -

US Patent 5,776,671 Filed September 26, 1997. Diagnostic and prognostic ELISA assays of serum .alpha.-N-acetylgalactosaminidase for influenza

Abstract:Influenza virus-infected cells secrete .alpha.-N-acetylgalactosaminidase into the blood stream, resulting in the deglycosylation of the Gc protein. This inactivates the MAF precursor activity of the Gc protein, leading to immunosuppression. Thus, the .alpha.-N-acetylgalactosaminidase activity in a patient's bloodstream can serve as a diagnostic and prognostic index. Antibody-sandwich ELISA method and kits for influenza virus specific .alpha.-N-acetylgalactosaminidase as an antigen were developed to detect serum or plasma .alpha.-N-acetylgalactosaminidase activity in influenza infected patients and are used as a diagnostic/prognostic index.
- - - - - - -

US Patent: 5,985,545. Filed March 13, 1998. Diagnostic and prognostic ELISA assays of serum .alpha.-N-acetylgalactosaminidase for AIDS

Abstract: HIV- virus-infected cells secrete .alpha.-N-acetylgalactosaminidase into the blood stream, resulting in the deglycosylation of the Gc protein. This inactivates the MAF precursor activity of the Gc protein, leading to immunosuppression. Thus, the .alpha.-N-acetylgalactosaminidase activity in a patient's bloodstream can serve as a diagnostic and prognostic index. Antibody-sandwich ELISA method and kits for HIV virus specific .alpha.-N-acetylgalactosaminidase as an antigen were developed to detect serum or plasma .alpha.-N-acetylgalactosaminidase activity in AIDS/HIV-infected patients and are used as a diagnostic/prognostic index.
- - - - - - -

US Patent 5,998,132 Filed February 8, 1999. Method and apparatus for detecting cancer, influenza, or HIV based on .alpha.-N-acetyl-galactosaminidase detection.

Abstract: HIV- and influenza virus-infected cells secrete .alpha.-N-acetylgalactosaminidase into the blood stream. Secretion of .alpha.-N-acetylgalactosaminidase is also associated with cancer. Elevated levels of .alpha.-N-acetylgalactosaminidase in the blood stream result in the deglycosylation of the Gc protein. This inactivates the MAF precursor activity of the Gc protein, leading to immunosuppression. Thus, the .alpha.-N-acetylgalactosaminidase activity in a patient's bloodstream can serve as a diagnostic and prognostic index. Antibody-sandwich ELISA methods and kits for .alpha.-N-acetylgalactosaminidase as an antigen were developed to detect serum or plasma .alpha.-N-acetylgalactosaminidase activity in patients and are used as a diagnostic/prognostic index.

US Patent 5,641,747. Filed July 25, 1994. Popoff; Steven N. (Warrington, PA), Schneider; Gary B. (Gurnee, IL) Treatment of osteopetrotic diseases.

Abstract: Bone resorption by osteoclast cells is promoted by activated vitamin D-binding factor, thereby providing an effective treatment for osteopetrosis. Conversely, inflammation-mediated bone loss is inhibited with antibody against the activated factor, providing a treatment for inflammation-mediated osteolytic diseases such as osteoporosis, osteoarthritis, rheumatoid arthritis and periodontal disease. The antibodies are further utilized in an antigen binding assay for diagnosing inflammation-mediated bone loss.

Notes: "To minimize any possible immunologic reaction from administration of DBF-MAF, it is preferred that the patient would receive only DBF-MAF derived from the blood of the same species. Similarly, the risk of immunologic reaction in individuals would be minimized by administering only the same variant of DBF-MAF, in situations wherein there is intraspecies DBP polymorphism. For example, a Gc1 human patient would receive Gc1MAF, that is, GcMAF generated from enzymatic cleavage of group specific component type Gc1. However, the risk of immune reaction from cross-species administration of DBP-MAF is believed minimal due to the high level of evolutionary conservation in that molecule. As demonstrated hereinafter, ia and op rats tolerated treatment with human DBP-MAF (GcMAF). "

Related Scientific papers: A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats.

Effects of vitamin D binding protein-macrophage activating factor (DBP-MAF) infusion on bone resorption in two osteopetrotic mutations

Evidence for Continuous Basal Generation of Gc-MAF: Absence in Infantile Osteopetrosis and Restoration After Bone Marrow Transplant